Bioxytran Inc.

BIXT

ORGANIZATION AND BUSINESS Bioxytran, Inc. is a clinical stage pharmaceutical company developing platform technologies in the fields of Glycovirology, Hypoxia and Degenerative Diseases to eliminate viruses and prolong lifespan using carbohydrate drug design. On September 21, 2018, the Company was reorganized into Bioxytran through a reverse merger to focus on the development, manufacturing and c…

Valuation & Multiples

Based on TTM earnings · Diluted shares

Market Cap$3M

EPS-$0.03

P/E-0.77

P/FCF–

EV/EBITDA-0.67

FCF Yield–

Div. Yield–

Net Debt/FCF–

Bioxytran Inc. intrinsic value

52-Week Range

$0.02$0.07

Profitability & Returns

TTM as of 2026-06 · YoY vs prior year · ROIC = NOPAT / invested capital

Revenue

N/A

Net Income (TTM)

-$3M

▲ +10.3% YoY

Op. Margin

–

ROIC

-6064.93%

▼ -5903.2pp YoY

Cash Flow & Balance Sheet

FCF = operating cash flow + capex · Net debt = total debt − cash · Balance sheet from latest filing

FCF

N/A

Op. Cash Flow (TTM)

-$874K

▼ -38.1% YoY

Net Debt

-$177K

Net Cash Position

Cash & Equiv.

$177K

Continue Research

Quality Scorecard

Is this a high-quality business?

Dividends

Payout safety and growth

Intrinsic Value

What is it worth?

Financials

Full income, cash flow, balance sheet

Peers

Pharmaceutical Preparations · Pick stocks to compare with BIXT

CompareIntrinsic value

LEXXLexaria Bioscience Corp.

$3.49-7.43%10

CLNNClene Inc.

$3.83-1.79%0

PLPLPlandai Biotechnology Inc.

$0.00+0.00%30

RGBPRegen Biopharma Inc.

$0.00+0.00%25

SERSerina Therapeutics Inc.

$1.94+2.65%40

HINDVyome Holdings, Inc

$1.80+2.86%20

SNGXSoligenix Inc.

$0.36-3.81%10

BFRGBullfrog AI Holdings Inc.

$0.49-3.56%40

Bioxytran (BIXT) in three numbers

Quality score: 25/100; Best check: margin trend, +302.1pp. Weakest: return on capital, -6064.9%.; Quality
Dividend: None; No dividend in the SEC filings we hold.; Dividends
P/E: -0.77; Negative: a loss over the last twelve months.; Financials

Questions about Bioxytran

Is Bioxytran a high-quality business?

Bioxytran scores 25 out of 100 on Intrinsiqq's quality score, which makes it a lower-quality business on these measures. The score blends 5 checks computed from SEC filings. Its best check is margin trend at +302.1pp, and its weakest is return on capital at -6064.9%. The Quality tab shows every check against its target.

Does Bioxytran (BIXT) pay a dividend?

No. Bioxytran (BIXT) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.

Source: 10-Q filed 14 Aug 2026 (period ending 30 Jun 2026), SEC. Price: last close 30 Oct 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.

Spot a number that looks wrong? Check it in BIXT's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing BIXT

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.